Press Release

Transcend Therapeutics Announces Completion of Acquisition by Otsuka Pharmaceutical

Transcend Therapeutics Receives FDA National Priority Voucher for TSND-201 in PTSD

Otsuka Pharmaceutical to Acquire Transcend Therapeutics

IMPACT-1 Study Published in JAMA Psychiatry: Results of TSND-201 (Methylone) in Patients with Severe PTSD

New Data Demonstrating the Mechanism of Action of TSND-201 (methylone) for the Treatment of PTSD Published in Neuropsychopharmacology

Transcend Therapeutics Receives Breakthrough Therapy Designation for TSND- 201 (methylone) for the Treatment of PTSD

Transcend Therapeutics Presents Positive Phase 2 Results of the Placebo-Controlled IMPACT-1 Study of PTSD at American Society of Clinical Psychopharmacology (ASCP) Annual Meeting Supporting TSND-201 as a Rapid, Robust, and Long-Lasting Treatment for PTSD

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of
TSND-201 in PTSD

Transcend Therapeutics Presents New Data from the Open-Label Portion of the IMPACT-1 Study and Further Data Supporting the Neuroplasticity Mechanism of TSND-201

Transcend Therapeutics Presents New Data At ASCP Demonstrating Improvements In Functioning And Sleep-Related Symptoms in PTSD Patients Treated with TSND-201 (Methylone)

Transcend Therapeutics announces publication of new preclinical data demonstrating TSND-201 (methylone) is a rapid-acting neuroplastogen with fewer off-target effects than MDMA

Transcend Therapeutics Announces Positive Open-Label Data from IMPACT-1